FDA
-
-
-
-
-
-
-
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company
-
-
-
-
-
-
-
Neos Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results
-
-
-
-
-
-
-
Neos Therapeutics (NEOS) Launches Cotempla XR-ODT Extended-Release Orally Disintegrating Tablets for Treatment of ADHD in Patients 6 to 17 Years Old
-
-
-
-
-
-
-
Neos Therapeutics Reports Second Quarter 2017 Financial Results
-
-
-
-
-
-
-
Neos Therapeutics (NEOS) Gains as Traders Await News Related to Cotempla XR-ODT
-
-
-
-
-
-
-
Neos Therapeutics to Host Fourth Quarter and Year-End 2016 Financial Results Conference Call on March 14, 2017
-
-
-
-
-
-
-
Neos Therapeutics (NEOS) Completes XR-ODT NDA Resubmission
-
322,217 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

